

Buchanan Ingersoll
ATTORNEYS

Robert G. Pinco
202 452 7901
pincorg@bipc.com

1776 K Street, N.W.
Suite 800
Washington, DC 20006-2365

T 202 452 7900
F 202 452 7989
www.buchananingersoll.com

8596 03 NOV 24 P1:05

July 25, 2003

Via E-mail and Federal Express

Laura E. Shay
Regulatory Project Manager
Division of Over-The-Counter Drug Products HFD-560
U.S. Food and Drug Administration
9201 Corporate Boulevard
Rockville, Maryland 20850

Re: Merck TEA

Dear Ms. Shay:

The following items should remain confidential as you release the Time and Extent documentation on Eusolex 6300, which you identified in your TEA Notice of Eligibility as Enzacamene (Methyl Benzylidene Camphor):

- **TEA, Part III**
Marketing Information for Eusolex 6300 including the corresponding Attachments E, F, and G.
- **TEA Part II, B**
'Method of Synthesis and Purification' including Attachment B : Manufacturing Principle

If you have any questions with regard to this matter, please do not hesitate to call me at (202) 452-7901.

Sincerely,



Robert G. Pinco

RGP/CMD
43560-000001

2003N-0233

LET 1